Reporter brief
The Use of Senolytic Agent to Improve the Benefit of Platelet-Rich Plasma and Losartan for Treatment of Femoroacetabular Impingement and Labral Tear: A Pilot Study
What happened
Trial registry update: UNKNOWN. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract contains no outcome data, so effectiveness of fisetin as an adjunct to PRP and losartan cannot be evaluated.
- No sample size is reported, making it impossible to assess whether the pilot had adequate power or whether results would generalize.
- The mechanism by which fisetin was hypothesized to work (eliminating senescent cells in PRP) was not tested or validated in the reported material.
Study design and sample
Rct; Human.
Patients suffering from femoroacetabular impingement and labral tear who are planning to undergo hip arthroscopy, recruited from The Steadman Clinic
- Design
- Rct
- Sample
- —
- Journal
- Steadman Philippon Research Institute
- Published
- Apr 16, 2024
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.